Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies

BACKGROUND: This study aimed to define the maximally tolerated dose (MTD) of sunitinib combined with two different infusion schedules of ifosfamide. METHODS: Patients with advanced solid tumours, good performance score, good organ function, and no standard therapy available were eligible. Continuous...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Hamberg, P, Steeghs, N, Loos, W J, van de Biessen, D, den Hollander, M, Tascilar, M, Verweij, J, Gelderblom, H, Sleijfer, S
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group 2010
Pynciau:
Clinical Study
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2883699/
https://ncbi.nlm.nih.gov/pubmed/20485286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605696
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg